Your browser doesn't support javascript.
loading
Neutralization potency of the 2023-24 seasonal influenza vaccine against circulating influenza H3N2 strains.
Huang, Xiande; Cheng, Ziqi; Lv, Yake; Li, Weixuan; Liu, Xiaoyu; Huang, Weijin; Zhao, Chenyan.
Afiliación
  • Huang X; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, China.
  • Cheng Z; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, China.
  • Lv Y; Center of Vaccine Clinical Evaluation, Institute for Immunization Program, Shaanxi Provincial Centre for Disease Control and Prevention, Xi'an, Shaanxi Province, China.
  • Li W; Center of Vaccine Clinical Evaluation, Institute for Immunization Program, Shaanxi Provincial Centre for Disease Control and Prevention, Xi'an, Shaanxi Province, China.
  • Liu X; Center of Vaccine Clinical Evaluation, Institute for Immunization Program, Shaanxi Provincial Centre for Disease Control and Prevention, Xi'an, Shaanxi Province, China.
  • Huang W; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, China.
  • Zhao C; Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, China.
Hum Vaccin Immunother ; 20(1): 2380111, 2024 Dec 31.
Article en En | MEDLINE | ID: mdl-39205645
ABSTRACT
Seasonal influenza is a severe disease that significantly impacts public health, causing millions of infections and hundreds of thousands of deaths each year. Seasonal influenza viruses, particularly the H3N2 subtype, exhibit high antigenic variability, often leading to mismatch between vaccine strains and circulating strains. Therefore, rapidly assessing the alignment between existing seasonal influenza vaccine and circulating strains is crucial for enhancing vaccine efficacy. This study, based on a pseudovirus platform, evaluated the match between current influenza H3N2 vaccine strains and circulating strains through cross-neutralization assays using clinical human immune sera against globally circulating influenza virus strains. The research results show that although mutations are present in the circulating strains, the current H3N2 vaccine strain still imparting effective protection, providing a scientific basis for encouraging influenza vaccination. This research methodology can be sustainably applied for the neutralization potency assessment of subsequent circulating strains, establishing a persistent methodological framework.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pruebas de Neutralización / Vacunas contra la Influenza / Gripe Humana / Subtipo H3N2 del Virus de la Influenza A / Anticuerpos Neutralizantes / Anticuerpos Antivirales Límite: Adult / Humans Idioma: En Revista: Hum Vaccin Immunother Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pruebas de Neutralización / Vacunas contra la Influenza / Gripe Humana / Subtipo H3N2 del Virus de la Influenza A / Anticuerpos Neutralizantes / Anticuerpos Antivirales Límite: Adult / Humans Idioma: En Revista: Hum Vaccin Immunother Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos